Patient demographics and baseline characteristics
| Demographic statistic/category . | Patients treated, N = 62 . |
|---|---|
| Median age, y (range) | 56 (26-83) |
| Male sex, n (%) | 42 (68) |
| Ethnicity, n (%) | |
| White | 48 (77) |
| Black | 4 (7) |
| Hispanic | 0 |
| Asian | 8 (13) |
| Other | 2 (3) |
| Median time since initial CML diagnosis, mo (range) | 50.0 (11-234) |
| ECOG performance status, n (%) | |
| 0 | 41 (66) |
| 1 | 20 (32) |
| 2 | 1 (2) |
| 3 | 0 |
| Type of TKIs previously received, n (%) | |
| Imatinib | 62 (100) |
| Dasatinib | 34 (55) |
| Nilotinib | 22 (36) |
| Other | 9 (15) |
| Number of TKIs previously received, n (%) | |
| 1 | 16 (26) |
| 2 | 30 (48) |
| ≥ 3 | 16 (26) |
| Other previous leukemia treatment, n (%) | |
| Hydroxyurea | 35 (56) |
| Interferon | 23 (37) |
| Cytarabine | 10 (16) |
| CHR status at study entry, n (%) | |
| CHR+ | 15 (24) |
| CHR− | 47 (76) |
| Demographic statistic/category . | Patients treated, N = 62 . |
|---|---|
| Median age, y (range) | 56 (26-83) |
| Male sex, n (%) | 42 (68) |
| Ethnicity, n (%) | |
| White | 48 (77) |
| Black | 4 (7) |
| Hispanic | 0 |
| Asian | 8 (13) |
| Other | 2 (3) |
| Median time since initial CML diagnosis, mo (range) | 50.0 (11-234) |
| ECOG performance status, n (%) | |
| 0 | 41 (66) |
| 1 | 20 (32) |
| 2 | 1 (2) |
| 3 | 0 |
| Type of TKIs previously received, n (%) | |
| Imatinib | 62 (100) |
| Dasatinib | 34 (55) |
| Nilotinib | 22 (36) |
| Other | 9 (15) |
| Number of TKIs previously received, n (%) | |
| 1 | 16 (26) |
| 2 | 30 (48) |
| ≥ 3 | 16 (26) |
| Other previous leukemia treatment, n (%) | |
| Hydroxyurea | 35 (56) |
| Interferon | 23 (37) |
| Cytarabine | 10 (16) |
| CHR status at study entry, n (%) | |
| CHR+ | 15 (24) |
| CHR− | 47 (76) |
CML indicates chronic myeloid leukemia; ECOG, Eastern Cooperative Oncology Group; TKI, tyrosine kinase inhibitor; and CHR, complete hematologic response.